Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity

Cell Reports

Volumn 6, Issue 3, 2014, Pages 514-527

  Almendro, Vanessa ^a,b,c,d   Cheng, Yu Kang ^a,e   Randles, Amanda ^a,e,f   Itzkovitz, Shalev ^g,h   Marusyk, Andriy ^a,b,c   Ametller, Elisabet ^d   Gonzalez Farre, Xavier ^d   Muñoz, Montse ^d   Russnes, HegeG ^i,j,k   Helland, Åslaug ^i,j,k   Rye, IngaH ^i,j   Borresen Dale, Anne Lise ^i,j   Maruyama, Reo ^a,b,c   vanOudenaarden, Alexander ^g,l   Dowsett, Mitchell ^m   Jones, RobinL ^m,n   Reis Filho, Jorge ^m,o   Gascon, Pere ^d   Gönen, Mithat ^o   Michor, Franziska ^a,e   Polyak, Kornelia ^a,b,c,p,q   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HOSPITAL CLÍNIC   (Spain)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h WEIZMANN INSTITUTE OF SCIENCE   (Israel)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF OSLO   (Norway)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l HUBRECHT INSTITUTE   (Netherlands)

^m ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁿ SEATTLE CANCER CARE ALLIANCE   (United States)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^p HARVARD STEM CELL INSTITUTE   (United States)

^q BROAD INSTITUTE OF MIT AND HARVARD   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; KI 67 ANTIGEN;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CELL HETEROGENEITY; CELLULAR DISTRIBUTION; CENTROMERE; CHROMOSOME 8; COMPUTER MODEL; COMPUTER SIMULATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SINGLE CELL ANALYSIS; STOCHASTIC MODEL; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENETIC HETEROGENEITY; GENETIC VARIATION; GENOTYPE; HUMANS; MODELS, BIOLOGICAL; PHENOTYPE;

EID: 84893830795     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.12.041     Document Type: Article

References (51)

1. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
2. Almendro V., Marusyk A., Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu. Rev. Pathol. 2013, 8:277-302.
3. Bloushtain-Qimron N., Yao J., Snyder E.L., Shipitsin M., Campbell L.L., Mani S.A., Hu M., Chen H., Ustyansky V., Antosiewicz J.E., et al. Cell type-specific DNA methylation patterns in the human breast. Proc. Natl. Acad. Sci. USA 2008, 105:14076-14081.
4. Burcombe R., Wilson G.D., Dowsett M., Khan I., Richman P.I., Daley F., Detre S., Makris A. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res. 2006, 8:R31.
5. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
6. Collecchi P., Baldini E., Giannessi P., Naccarato A.G., Passoni A., Gardin G., Roncella M., Evangelista G., Bevilacqua G., Conte P.F. Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. Eur. J. Cancer 1998, 34:1701-1704.
7. Dave B., Mittal V., Tan N.M., Chang J.C. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012, 14:202.
8. Ding L., Ley T.J., Larson D.E., Miller C.A., Koboldt D.C., Welch J.S., Ritchey J.K., Young M.A., Lamprecht T., McLellan M.D., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
9. Efron B., Tibshirani R.J. An Introduction to the Bootstrap 1993, Chapman & Hall, London.
10. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
11. Esserman L.J., Berry D.A., DeMichele A., Carey L., Davis S.E., Buxton M., Hudis C., Gray J.W., Perou C., Yau C., et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J.Clin. Oncol. 2012, 30:3242-3249.
12. Fidler I.J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 1978, 38:2651-2660.
13. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., Wickerham D.L., Begovic M., DeCillis A., Robidoux A., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J.Clin. Oncol. 1998, 16:2672-2685.
14. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N.Engl. J. Med. 2012, 366:883-892.
15. Geyer F.C., Weigelt B., Natrajan R., Lambros M.B., de Biase D., Vatcheva R., Savage K., Mackay A., Ashworth A., Reis-Filho J.S. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J.Pathol. 2010, 220:562-573.
16. Heppner G.H., Miller B.E. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev. 1983, 2:5-23.
17. Hernandez L., Wilkerson P.M., Lambros M.B., Campion-Flora A., Rodrigues D.N., Gauthier A., Cabral C., Pawar V., Mackay A., A'hern R., et al. Genomic and mutational profiling of ductal carcinomas insitu and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J.Pathol. 2012, 227:42-52.
18. Hess K.R., Anderson K., Symmans W.F., Valero V., Ibrahim N., Mejia J.A., Booser D., Theriault R.L., Buzdar A.U., Dempsey P.J., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J.Clin. Oncol. 2006, 24:4236-4244.
19. Honeth G., Bendahl P.O., Ringnér M., Saal L.H., Gruvberger-Saal S.K., Lövgren K., Grabau D., Fernö M., Borg A., Hegardt C. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008, 10:R53.
20. Houssami N., Macaskill P., von Minckwitz G., Marinovich M.L., Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur. J. Cancer 2012, 48:3342-3354.
21. Kaufmann M., Hortobagyi G.N., Goldhirsch A., Scholl S., Makris A., Valagussa P., Blohmer J.U., Eiermann W., Jackesz R., Jonat W., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J.Clin. Oncol. 2006, 24:1940-1949.
22. Kedrin D., Gligorijevic B., Wyckoff J., Verkhusha V.V., Condeelis J., Segall J.E., van Rheenen J. Intravital imaging of metastatic behavior through a mammary imaging window. Nat. Methods 2008, 5:1019-1021.
23. Landau D.A., Carter S.L., Getz G., Wu C.J. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia 2013, Published online August 27, 2013. 10.1038/leu.2013.248.
24. Lee H.E., Kim J.H., Kim Y.J., Choi S.Y., Kim S.W., Kang E., Chung I.Y., Kim I.A., Kim E.J., Choi Y., et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br. J. Cancer 2011, 104:1730-1738.
25. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J.Natl. Cancer Inst. 2008, 100:672-679.
26. Liu R., Wang X., Chen G.Y., Dalerba P., Gurney A., Hoey T., Sherlock G., Lewicki J., Shedden K., Clarke M.F. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N.Engl. J. Med. 2007, 356:217-226.
27. Magurran A.E. Measuring Biological Diversity 2004, Blackwell, Malden.
28. Maley C.C., Galipeau P.C., Finley J.C., Wongsurawat V.J., Li X., Sanchez C.A., Paulson T.G., Blount P.L., Risques R.A., Rabinovitch P.S., Reid B.J. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 2006, 38:468-473.
29. Marusyk A., Polyak K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 2010, 1805:105-117.
30. Marusyk A., Almendro V., Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nat. Rev. Cancer 2012, 12:323-334.
31. Matsubara N., Mukai H., Fujii S., Wada N. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast Cancer Res. Treat. 2013, 137:203-212.
32. Merlo L.M., Pepper J.W., Reid B.J., Maley C.C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 2006, 6:924-935.
33. Merlo L.M., Shah N.A., Li X., Blount P.L., Vaughan T.L., Reid B.J., Maley C.C. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev. Res. (Phila.) 2010, 3:1388-1397.
34. Mroz E.A., Tward A.D., Pickering C.R., Myers J.N., Ferris R.L., Rocco J.W. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer 2013, 119:3034-3042.
35. Navin N., Kendall J., Troge J., Andrews P., Rodgers L., McIndoo J., Cook K., Stepansky A., Levy D., Esposito D., et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472:90-94.
36. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.K., Attar N., Sazegar H., et al. Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
37. Nikolsky Y., Sviridov E., Yao J., Dosymbekov D., Ustyansky V., Kaznacheev V., Dezso Z., Mulvey L., Macconaill L.E., Winckler W., et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res. 2008, 68:9532-9540.
38. Park S.Y., Gönen M., Kim H.J., Michor F., Polyak K. Cellular and genetic diversity in the progression of insitu human breast carcinomas to an invasive phenotype. J.Clin. Invest. 2010, 120:636-644.
39. Park S.Y., Lee H.E., Li H., Shipitsin M., Gelman R., Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin. Cancer Res. 2010, 16:876-887.
40. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
41. Polyak K. Heterogeneity in breast cancer. J.Clin. Invest. 2011, 121:3786-3788.
42. Roesch A., Vultur A., Bogeski I., Wang H., Zimmermann K.M., Speicher D., Körbel C., Laschke M.W., Gimotty P.A., Philipp S.E., et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 2013, 23:811-825.
43. Sakai W., Swisher E.M., Karlan B.Y., Agarwal M.K., Higgins J., Friedman C., Villegas E., Jacquemont C., Farrugia D.J., Couch F.J., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120.
44. Schiffer L.M., Braunschweiger P.G., Stragand J.J., Poulakos L. The cell kinetics of human mammary cancers. Cancer 1979, 43:1707-1719.
45. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
46. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., Nikolskaya T., Serebryiskaya T., Beroukhim R., Hu M., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
47. Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., Juul N., Leong C.O., Calogrias D., Buraimoh A., et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J.Clin. Oncol. 2010, 28:1145-1153.
48. Stephens P.J., Tarpey P.S., Davies H., Van Loo P., Greenman C., Wedge D.C., Nik-Zainal S., Martin S., Varela I., Bignell G.R., et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486:400-404. Oslo Breast Cancer Consortium (OSBREAC).
49. Turner N.C., Reis-Filho J.S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012, 13:e178-e185.
50. van de Ven S., Smit V.T., Dekker T.J., Nortier J.W., Kroep J.R. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat. Rev. 2011, 37:422-430.
51. Yap T.A., Gerlinger M., Futreal P.A., Pusztai L., Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med. 2012, 4:127ps110.